JAML transmembrane and co-signaling domains for chimeric antigen receptors

TW202641830APending Publication Date: 2026-10-16KITE PHARMA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114149759
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-12-18
Filing Date
2025-12-17
Publication Date
2026-10-16

Smart Images

  • Figure TWG2TA001080724_001
    Figure TWG2TA001080724_001
  • Figure TWG2TA001080724_002
    Figure TWG2TA001080724_002
  • Figure TWG2TA001080724_003
    Figure TWG2TA001080724_003
Patent Text Reader

Abstract

The present disclosure relates to the field of cell therapy, and more specifically, to chimeric antigen receptor (CAR) cell therapy. In one embodiment, the disclosure provides CAR-T constructs comprising transmembrane and / or co-stimulatory cytoplasmic domains of JAML. In one embodiment, the disclosure provides CAR-T cells that co-express two CAR-T constructs, or a bicistronic construct, one of which comprises a JAML transmembrane and / or co-stimulatory domain. In one embodiment, the disclosure provides CAR-T cells that co-express a CAR-T construct and a full length JAML construct. In one embodiment, the disclosure provides a chimeric construct comprising a TGFbeta- receptor with an intracellular JAML domain, or a fragment thereof, and cells expressing the same. In one embodiment, the disclosure provides methods of treating cancer and autoimmune disorders with the constructs and cells of the disclosure.
Need to check novelty before this filing date? Find Prior Art